Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00522145 · ClinicalTrials.gov registry record · Phase 2

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Kadmon Corporation.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
10
Study locations

NCT00522145 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Kadmon Corporation. The registered enrollment target is 41 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The trial reports 10 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00522145, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Kadmon Corporation.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG XL647

Study Locations (10)

California

  • Ronald Yanagihara - Gilroy
  • University of California Davis Cancer Center - Sacramento
  • Oncology Division and General Clincial Research, Stanford University Medical Center - Stanford

Ohio

  • Case Western Reserve University, University Hospitals of Cleveland - Cleveland
  • Signal Point Clinical Research Center - Middletown

Indiana

  • Cancer Care Center, Inc. P.C. - New Albany

Maryland

  • Washington County Hospital, The Center for Clinical Research - Hagerstown

Michigan

  • Wayne State University, Wertz Clinical Cancer Center, Karmanos Center - Detroit

New York

  • Memorial Sloan-Kettering Cancer Center - New York

North Carolina

  • New Bern Cancer Care Oncology - New Bern

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2007-05
Est. Completion 2010-02
Phase Phase 2

Sponsor

Kadmon Corporation

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00522145

The ClinicalTrials.gov registry entry for NCT00522145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which XL647 is the first listed.

NCT00522145 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Ohio, Indiana.

Frequently Asked Questions

What is clinical trial NCT00522145 about?

NCT00522145 is a clinical study titled "Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib". The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.

What is the current status of trial NCT00522145?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-05. Estimated completion is 2010-02.

What conditions does trial NCT00522145 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT00522145?

The interventions under investigation include: XL647 (DRUG).

Who is sponsoring clinical trial NCT00522145?

This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00522145 being conducted?

This trial has 10 study locations across California, Indiana, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.